Spruce Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spruce Biosciences (SPRB).

Price Target Range — 10 Quarters

Analyst Consensus — 12 Analysts

2S.Buy

8Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$156Upside to Avg. PT+269.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$144
Sep 17, 2026	Lake Street	Daniel Brims	Initiate	Buy	$149
Aug 17, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$123→$104
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$150→$144
Jul 13, 2026	B. Riley Securities	Madison El-Saadi	Initiate	Buy	$160
Jun 16, 2026	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$123
Jun 9, 2026	Jones Trading	Catherine Novack	Initiate	Buy	$135
Jun 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$200→$150
May 14, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$170→$150
Apr 27, 2026	Craig-Hallum	Albert Lowe	Initiate	Buy	$140
Mar 10, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$180→$170
Mar 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$200
Feb 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$220→$200
Dec 23, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$283
Dec 22, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$220
Dec 3, 2025	Leerink Partners	Joseph Schwartz	Upgrade	Market Perform→Outperform	$160
Nov 11, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$254→$259
Oct 28, 2025	JMP Securities	Jonathan Wolleben	Upgrade	Market Perform→Market Outperform	$254
Oct 21, 2025	Leerink Partners	Joseph Schwartz	PT Raise	Market Perform	$10→$160
Apr 16, 2025	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$2→$1

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.

Benzinga Newsdesk

Spruce Biosciences Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Spruce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

PRO
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

People Also Watch

People Also Watch

Spruce Biosciences Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Spruce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

PROLake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

PROGuggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PROCitizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PROB. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PROGuggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

People Also Watch

People Also Watch

PRO
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

PRO
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123